These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31203390)

  • 21. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
    Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Mabro M; Artru P; Gilles V; Lotz JP; Izrael V; Krulik M;
    Eur J Cancer; 2001 May; 37(8):1000-5. PubMed ID: 11334725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
    Van Cutsem E; Prenen H; D'Haens G; Bennouna J; Carrato A; Ducreux M; Bouché O; Sobrero A; Latini L; Staines H; Oum'Hamed Z; Dressler H; Studeny M; Capdevila J
    Ann Oncol; 2015 Oct; 26(10):2085-91. PubMed ID: 26272806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of addition of bevacizumab to oxaliplatin-based preoperative chemotherapy in colorectal cancer with liver metastasis- a single institution experience.
    Cvetanovic A; Vrbic S; Filipovic S; Pejcic I; Milenkovic D; Milenkovic N; Zivkovic N
    J BUON; 2013; 18(3):641-6. PubMed ID: 24065477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II).
    Rauwerdink P; van de Vlasakker VCJ; Wassenaar ECE; Rovers KP; Los M; Herbschleb KH; Creemers GM; Thijs AMJ; Raicu MG; Huysentruyt CJR; van der Hoeven EJRJ; Nederend J; Peeters RYM; Deenen MJ; Elias SG; Fijneman RJA; Constantinides A; Kranenburg O; Burger PWA; Nienhuijs SW; Wiezer RJ; Lurvink RJ; de Hingh IHJT; Boerma D
    Eur J Surg Oncol; 2024 Sep; 50(9):108487. PubMed ID: 38905732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
    Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
    Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
    Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
    Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
    Khakoo S; Chau I; Pedley I; Ellis R; Steward W; Harrison M; Baijal S; Tahir S; Ross P; Raouf S; Ograbek A; Cunningham D;
    Clin Colorectal Cancer; 2019 Dec; 18(4):280-291.e5. PubMed ID: 31451367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
    Infante JR; Reid TR; Cohn AL; Edenfield WJ; Cescon TP; Hamm JT; Malik IA; Rado TA; McGee PJ; Richards DA; Tarazi J; Rosbrook B; Kim S; Cartwright TH
    Cancer; 2013 Jul; 119(14):2555-63. PubMed ID: 23605883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.